Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2023 16:05 ET | Source: ALX Oncology

ALX Oncology Announces November Investor Conference Participation

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block...
October 10, 2023 16:05 ET | Source: ALX Oncology

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that...
October 05, 2023 08:00 ET | Source: ALX Oncology

ALX Oncology Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that...
October 04, 2023 16:10 ET | Source: ALX Oncology

ALX Oncology Announces Proposed Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that...
October 03, 2023 06:00 ET | Source: ALX Oncology

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

-- Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors -- Interim efficacy results showed the confirmed overall response rate for evorpacept combination...
October 02, 2023 16:05 ET | Source: ALX Oncology

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that...
September 06, 2023 08:00 ET | Source: ALX Oncology

ALX Oncology Realigns Executive Leadership Team

Jason Lettmann appointed as Chief Executive OfficerDr. Jaume Pons transitions to Chief Scientific Officer SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings...
August 31, 2023 07:00 ET | Source: ALX Oncology

ALX Oncology Announces September Investor Conference Participation

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block...
August 10, 2023 16:01 ET | Source: ALX Oncology

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

Advancing Phase 2/3 ASPEN-06 gastric cancer trial with data update expected in Q423 Terminating azacitidine combination development programs: ASPEN-02 in MDS and ASPEN-05 in AML Continuing focus on...
June 26, 2023 07:00 ET | Source: ALX Oncology

ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block...